This article has been updated from a previous version.
NEW YORK, Jan 24 – Deltagen has licensed Aurora Biosciences’ green fluorescent protein technology for use in transgenic organisms, including knockout mice, the companies announced Wednesday.
The non-exclusive license applies to the United States, with the option of expanding the license overseas for additional fees. Financial details were not disclosed.
“Deltagen’s core technology is that we understand what genes do in vivo ,” said Deltagen vice president for commercial development Lars Barfod. “We create more than 350 mouse models a year, and GFP [green fluorescent protein] just adds to the arsenal that we have to identify drug targets,” he said.
Green fluorescent protein technology helps identify cellular expressions of a gene by enabling fluorescent detection of the phenotype, said Barfod. Applications of the technology include functional genomics, high-throughput screening assays, and gene profiling to assess the potential toxicity of compounds, according to an Aurora statement.
“Deltagen’s desire to use Aurora’s GFP technology to discover in vivo mammalian gene function information and to determine the disease relevance of mammalian genes is another example of the widespread use of Aurora’s GFP technology into our drug target discovery platform,” said Christopher Krueger, Aurora’s vice president for strategic alliances and legal affairs, in a statement.Deltagen has developed a database of potential drug targets, called Deltabase, that currently counts GlaxoSmithKlineBeecham and Pfizer as subscribers.